市場調査レポート

商品コード

1472276

バイオマーカーの世界市場：タイプ別、用途別、サービス別 - 機会分析・産業予測、2024～2033年

Biomarkers Market By Type, By Application, By Services : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日: 2024年03月01日
発行: Allied Market Research
ページ情報: 英文 347 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 5,730 829,474円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,389,696円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のバイオマーカーの市場規模は、2023年に464億米ドルに達し、2024～2033年にかけてCAGR 11.2%で成長し、2033年には1,342億米ドルに達すると予測されています。

バイオマーカーは、生物学的プロセス、健康状態、治療介入に対する反応に関する重要な情報を提供する測定可能な指標です。様々な体液、組織、あるいは画像データから見出されるこれらのマーカーは、病気の診断、予後、モニタリングにおいて重要な役割を果たします。客観的で定量可能な指標として機能し、臨床医が病気の存在、重症度、進行度を評価する際に役立ちます。バイオマーカーには、タンパク質、核酸、代謝産物、画像パラメータなど幅広いスペクトルが含まれ、生物学的システムの多様な性質を反映しています。

バイオマーカー市場は、慢性疾患の罹患率の上昇と、医薬品開発プロセスにおけるバイオマーカーの高い採用率により、予測期間中に大きな成長を記録すると予想されます。

慢性疾患の増加は、バイオマーカー市場の成長を推進する極めて重要な要因として浮上しています。近年、心血管疾患、がん、糖尿病、神経変性疾患などの有病率が世界的に急上昇しています。例えば、世界保健機関（WHO）の2024年報告書によると、2050年には3,500万人以上のがん患者が新たに診断されると推定されています。この急増は、座りがちなライフスタイル、不健康な食生活、高齢化など、いくつかの要因に起因しています。慢性疾患がヘルスケアシステムに大きな負担をかけ続ける中、効果的な疾病管理のために早期かつ正確な診断が重視されるようになっています。

バイオマーカーは、生物学的プロセスや状態を示す測定可能な指標であり、個人の生理学的状態に関する貴重な洞察を提供することで、疾病診断において重要な役割を果たしています。バイオマーカーは、早期発見、リスク評価、疾患進行のモニタリングを容易にし、タイムリーな介入と個別化された治療戦略を可能にします。例えば、アメリカのバイオテクノロジー企業であるGuardant Health社は、Guardant360 CDx検査を提供しています。Guardant360 CDx検査は、すべての固形がんに対する完全なゲノム検査としてFDAに承認されています。この検査は、基本的な血液検査から7日以内に包括的なゲノム検査結果を提供し、医師が十分な情報を得た上で治療法を選択するのに役立ちます。さらに、ゲノミクス、プロテオミクス、メタボロミクスの技術進歩により、臨床で使用されるバイオマーカーの範囲が広がり、様々な疾患の診断における有効性が向上しています。このように、慢性疾患の罹患率の増加は、市場の成長を促進すると予想されます。

医薬品開発プロセスにおけるバイオマーカーの採用急増は、バイオマーカー市場の成長を促進する極めて重要な要因です。バイオマーカーは、生物学的プロセスや治療介入に対する反応の測定可能な指標として定義され、医薬品開発プロセスにおいて不可欠なツールとなっています。バイオマーカーは、生物の生理学的・分子生物学的状態に関する正確かつリアルタイムの情報を提供できるため、製薬会社の創薬・薬剤開発へのアプローチ方法に革命をもたらしました。バイオマーカーは、前臨床試験から臨床試験までの様々な段階で、新薬の有効性、安全性、潜在的な副作用を客観的に評価する手段を提供します。これにより、医薬品開発のタイムラインを早め、成功の確率を高めることができます。例えば、国立医学図書館による2020年の報告書によると、バイオマーカーは創薬と開発のあらゆる段階で広く利用されています。バイオマーカーの活用は、創薬、開発、承認のプロセスをより効率的にする可能性を秘めています。そのため、創薬・開発プロセスにおけるバイオマーカー採用の増加は、市場の成長に大きく貢献すると期待されています。

しかし、データのセキュリティとプライバシーに関する懸念が、市場の成長を抑制する主要な懸念として浮上しています。ライフサイエンス業界は、患者記録、臨床試験情報、ゲノムデータなど、機密性の高い膨大なデータの収集、保管、分析に大きく依存しています。ヘルスケアプロセスのデジタル化が進み、クラウドコンピューティングやビッグデータ分析などの先端技術が採用されるにつれ、データ漏洩や不正アクセスのリスクは高まっています。そのため、データのセキュリティやプライバシーに関する懸念が市場の成長を抑制すると予想されます。

また、開発コストが高いことも市場の成長を抑制する可能性があります。バイオマーカーの発見と検証には多額の研究開発費がかかります。バイオマーカーの開発と検証にかかるコストが高いことは、特に中小企業におけるバイオマーカーの採用に悪影響を及ぼします。

バイオマーカー市場は、タイプ、用途、サービス、地域によって区分されます。タイプ別では、有効性バイオマーカー、安全性バイオマーカー、検証バイオマーカーに分けられます。用途別では、リスク評価、分子診断開発、疾病診断、創薬・市場開拓、製剤化、法医学用途、その他に分けられます。

サービス別では、製薬・サンプル調製、アッセイ開発、バイオマーカーバリデーション・検査、その他サービスに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（フランス、ドイツ、イタリア、スペイン、英国、その他の欧州）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、その他のアジア太平洋）、アジア太平洋（ブラジル、日本、インド、韓国、オーストラリア、アラビア、その他のアジア太平洋）で分析されます。

利害関係者にとっての主なメリット

本レポートは、2023～2033年までのバイオマーカー市場分析の市場セグメント、現在の動向、推定・動向分析、ダイナミクスを定量的に提供し、バイオマーカー市場の有力な市場機会を特定します。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの力を強調します。
バイオマーカー市場のセグメンテーションの詳細分析により、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
本レポートには、地域別および世界のバイオマーカー市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートのカスタマイズが可能です。

顧客の関心に応じた企業プロファイルの追加
国別または地域別の追加分析、市場規模と予測
クリスクロスセグメント分析、市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ
主要プレーヤーの詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）
世界／地域／国別レベルでのプレーヤーの市場シェア分析
SWOT分析

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 創薬・開発プロセスにおけるバイオマーカーの高い採用率。
  - 慢性疾患の急増
  - 法医学分析におけるバイオマーカー採用の増加。
- 抑制要因
  - バイオマーカー開発コストの高さ
- 機会
  - バイオマーカー開発のための民間団体と政府機関の協力。

第4章バイオマーカー市場：タイプ別

概要
有効性バイオマーカー
安全性バイオマーカー
バリデーションバイオマーカー

第5章バイオマーカー市場：用途別

概要
リスク評価
分子診断薬の開発
疾病診断
創薬と医薬品開発
医薬品製剤
法医学用途
その他

第6章バイオマーカー市場：サービス別

概要
サンプル調製
アッセイ開発
バイオマーカーバリデーション・検査
その他のサービス

第7章バイオマーカー市場：地域別

概要
北米
- 北米の創薬・市場開拓バイオマーカー市場：タイプ別
- 米国
- カナダ
- メキシコ
欧州
- 欧州の創薬・市場開拓バイオマーカー市場：タイプ別
- 英国
- フランス
- ドイツ
- イタリア
- スペイン
- その他の欧州
アジア太平洋
- アジア太平洋の創薬・市場開拓バイオマーカー市場：タイプ別
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋
ラテンアメリカ・中東・アフリカ
- ラテンアメリカ・中東・アフリカの創薬・市場開拓バイオマーカー市場：タイプ別
- ブラジル
- サウジアラビア
- 南アフリカ
- その他のラテンアメリカ・中東・アフリカ

第8章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2023年

第9章企業プロファイル

Abbott Laboratories
Agilent Technologies Inc.
Bio-Rad Laboratories, Inc.
GE Healthcare
Siemens AG
Thermo Fisher Scientific
Qiagen N.V
Merck KGaA
F. Hoffmann-La Roche AG
Revvity, Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 02. BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
TABLE 03. BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
TABLE 04. BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY REGION, 2023-2033 ($MILLION)
TABLE 05. GLOBAL BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 06. BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2023-2033 ($MILLION)
TABLE 07. BIOMARKERS MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC, BY REGION, 2023-2033 ($MILLION)
TABLE 08. BIOMARKERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2023-2033 ($MILLION)
TABLE 09. BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2023-2033 ($MILLION)
TABLE 10. GLOBAL DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 11. BIOMARKERS MARKET FOR CLINICAL TRIAL - PRE CLINICAL PHASE AND PHASE 1, BY REGION, 2023-2033 ($MILLION)
TABLE 12. BIOMARKERS MARKET FOR CLINICAL TRIAL PHASE 2, BY REGION, 2023-2033 ($MILLION)
TABLE 13. BIOMARKERS MARKET FOR CLINICAL TRIAL PHASE 3, BY REGION, 2023-2033 ($MILLION)
TABLE 14. BIOMARKERS MARKET FOR CLINICAL TRIAL COMMERCIAL PHASE, BY REGION, 2023-2033 ($MILLION)
TABLE 15. BIOMARKERS MARKET FOR DRUG FORMULATION, BY REGION, 2023-2033 ($MILLION)
TABLE 16. BIOMARKERS MARKET FOR FORENSIC APPLICATION, BY REGION, 2023-2033 ($MILLION)
TABLE 17. BIOMARKERS MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
TABLE 18. GLOBAL BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 19. BIOMARKERS MARKET FOR SAMPLE PREPARATION, BY REGION, 2023-2033 ($MILLION)
TABLE 20. BIOMARKERS MARKET FOR ASSAY DEVELOPMENT, BY REGION, 2023-2033 ($MILLION)
TABLE 21. BIOMARKERS MARKET FOR BIOMARKER VALIDATION AND TESTING, BY REGION, 2023-2033 ($MILLION)
TABLE 22. BIOMARKERS MARKET FOR OTHER SERVICES, BY REGION, 2023-2033 ($MILLION)
TABLE 23. BIOMARKERS MARKET, BY REGION, 2023-2033 ($MILLION)
TABLE 24. NORTH AMERICA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 25. NORTH AMERICA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 26. NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 27. NORTH AMERICA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 28. NORTH AMERICA BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 29. U.S. BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 30. U.S. BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 31. U.S. BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 32. CANADA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 33. CANADA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 34. CANADA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 35. MEXICO BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 36. MEXICO BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 37. MEXICO BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 38. EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 39. EUROPE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 40. EUROPE DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 41. EUROPE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 42. EUROPE BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 43. UK BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 44. UK BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 45. UK BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 46. FRANCE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 47. FRANCE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 48. FRANCE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 49. GERMANY BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 50. GERMANY BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 51. GERMANY BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 52. ITALY BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 53. ITALY BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 54. ITALY BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 55. SPAIN BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 56. SPAIN BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 57. SPAIN BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 58. REST OF EUROPE BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 59. REST OF EUROPE BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 60. REST OF EUROPE BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 61. ASIA-PACIFIC BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 62. ASIA-PACIFIC BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 63. ASIA-PACIFIC DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 64. ASIA-PACIFIC BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 65. ASIA-PACIFIC BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 66. JAPAN BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 67. JAPAN BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 68. JAPAN BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 69. CHINA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 70. CHINA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 71. CHINA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 72. INDIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 73. INDIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 74. INDIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 75. AUSTRALIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 76. AUSTRALIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 77. AUSTRALIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 78. SOUTH KOREA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 79. SOUTH KOREA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 80. SOUTH KOREA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 82. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 84. LAMEA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 85. LAMEA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 86. LAMEA DRUG DISCOVERY AND DEVELOPMENT BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 87. LAMEA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 88. LAMEA BIOMARKERS MARKET, BY COUNTRY, 2023-2033 ($MILLION)
TABLE 89. BRAZIL BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 90. BRAZIL BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 91. BRAZIL BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 92. SAUDI ARABIA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 93. SAUDI ARABIA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 94. SAUDI ARABIA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 95. SOUTH AFRICA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 96. SOUTH AFRICA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 97. SOUTH AFRICA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 98. REST OF LAMEA BIOMARKERS MARKET, BY TYPE, 2023-2033 ($MILLION)
TABLE 99. REST OF LAMEA BIOMARKERS MARKET, BY APPLICATION, 2023-2033 ($MILLION)
TABLE 100. REST OF LAMEA BIOMARKERS MARKET, BY SERVICES, 2023-2033 ($MILLION)
TABLE 101. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 102. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 103. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 104. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 105. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 106. AGILENT TECHNOLOGIES INC.: KEY EXECUTIVES
TABLE 107. AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
TABLE 108. AGILENT TECHNOLOGIES INC.: PRODUCT SEGMENTS
TABLE 109. AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
TABLE 110. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 111. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 112. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 113. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 114. GE HEALTHCARE: KEY EXECUTIVES
TABLE 115. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 116. GE HEALTHCARE: PRODUCT SEGMENTS
TABLE 117. GE HEALTHCARE: SERVICE SEGMENTS
TABLE 118. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 119. GE HEALTHCARE: KEY STRATERGIES
TABLE 120. SIEMENS AG: KEY EXECUTIVES
TABLE 121. SIEMENS AG: COMPANY SNAPSHOT
TABLE 122. SIEMENS AG: PRODUCT SEGMENTS
TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 124. SIEMENS AG: KEY STRATERGIES
TABLE 125. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
TABLE 126. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 127. THERMO FISHER SCIENTIFIC: PRODUCT SEGMENTS
TABLE 128. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 129. THERMO FISHER SCIENTIFIC: KEY STRATERGIES
TABLE 130. QIAGEN N.V: KEY EXECUTIVES
TABLE 131. QIAGEN N.V: COMPANY SNAPSHOT
TABLE 132. QIAGEN N.V: PRODUCT SEGMENTS
TABLE 133. QIAGEN N.V: PRODUCT PORTFOLIO
TABLE 134. QIAGEN N.V: KEY STRATERGIES
TABLE 135. MERCK KGAA: KEY EXECUTIVES
TABLE 136. MERCK KGAA: COMPANY SNAPSHOT
TABLE 137. MERCK KGAA: PRODUCT SEGMENTS
TABLE 138. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 139. MERCK KGAA: KEY STRATERGIES
TABLE 140. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 141. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 142. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
TABLE 143. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 144. F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 145. REVVITY, INC.: KEY EXECUTIVES
TABLE 146. REVVITY, INC.: COMPANY SNAPSHOT
TABLE 147. REVVITY, INC.: PRODUCT SEGMENTS
TABLE 148. REVVITY, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. BIOMARKERS MARKET, 2023-2033
FIGURE 02. SEGMENTATION OF BIOMARKERS MARKET,2023-2033
FIGURE 03. TOP IMPACTING FACTORS IN BIOMARKERS MARKET (2023 TO 2033)
FIGURE 04. TOP INVESTMENT POCKETS IN BIOMARKERS MARKET (2024-2033)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. BIOMARKERS MARKET, BY TYPE, 2023 AND 2033(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY COUNTRY 2023 AND 2033(%)
FIGURE 15. BIOMARKERS MARKET, BY APPLICATION, 2023 AND 2033(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY 2023 AND 2033(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC, BY COUNTRY 2023 AND 2033(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY 2023 AND 2033(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY 2023 AND 2033(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR DRUG FORMULATION, BY COUNTRY 2023 AND 2033(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR FORENSIC APPLICATION, BY COUNTRY 2023 AND 2033(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
FIGURE 23. BIOMARKERS MARKET, BY SERVICES, 2023 AND 2033(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR SAMPLE PREPARATION, BY COUNTRY 2023 AND 2033(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR ASSAY DEVELOPMENT, BY COUNTRY 2023 AND 2033(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR BIOMARKER VALIDATION AND TESTING, BY COUNTRY 2023 AND 2033(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF BIOMARKERS MARKET FOR OTHER SERVICES, BY COUNTRY 2023 AND 2033(%)
FIGURE 28. BIOMARKERS MARKET BY REGION, 2023 AND 2033(%)
FIGURE 29. U.S. BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 30. CANADA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 31. MEXICO BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 32. UK BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 33. FRANCE BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 34. GERMANY BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 35. ITALY BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 36. SPAIN BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 37. REST OF EUROPE BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 38. JAPAN BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 39. CHINA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 40. INDIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 41. AUSTRALIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 42. SOUTH KOREA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 43. REST OF ASIA-PACIFIC BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 44. BRAZIL BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 45. SAUDI ARABIA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 46. SOUTH AFRICA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 47. REST OF LAMEA BIOMARKERS MARKET, 2023-2033 ($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52. COMPETITIVE DASHBOARD
FIGURE 53. COMPETITIVE HEATMAP: BIOMARKERS MARKET
FIGURE 54. TOP PLAYER POSITIONING, 2023
FIGURE 55. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. AGILENT TECHNOLOGIES INC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 59. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 60. AGILENT TECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 61. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
FIGURE 62. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. GE HEALTHCARE: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 65. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 66. GE HEALTHCARE: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 67. SIEMENS AG: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 68. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 69. SIEMENS AG: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 70. THERMO FISHER SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
FIGURE 71. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 72. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 73. QIAGEN N.V: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 74. QIAGEN N.V: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 75. MERCK KGAA: NET SALES, 2021-2023 ($MILLION)
FIGURE 76. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 77. MERCK KGAA: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 78. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 79. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 80. REVVITY, INC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 81. REVVITY, INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 82. REVVITY, INC.: REVENUE SHARE BY REGION, 2023 (%)

Product Code: A00021

The global biomarkers market size was valued at $46.4 billion in 2023, and is projected to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033.

Biomarkers are measurable indicators that provide essential information about biological processes, health conditions, or responses to therapeutic interventions. These markers, found in various bodily fluids, tissues, or even imaging data, play a crucial role in diagnostics, prognosis, and monitoring of diseases. They serve as objectifiable and quantifiable measures, aiding clinicians in assessing the presence, severity, and progression of illnesses. Biomarkers cover a broad spectrum, including proteins, nucleic acids, metabolites, and imaging parameters, reflecting the diverse nature of biological systems.

The biomarkers market is expected to register significant growth during the forecast period owing to a rise in incidence of chronic diseases and high adoption of the biomarkers in the drug development process.

The rise in incidence of chronic diseases has emerged as a pivotal driver propelling the growth of the biomarkers market. In recent years, there has been a noteworthy surge in the prevalence of conditions such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders globally. For instance, according to the 2024 report by World Health Organization, it was estimated that over 35 million new cancer cases are expected to be diagnosed in 2050. This surge is attributed to several factors, such as sedentary lifestyles, unhealthy dietary habits, and an aging population. As chronic diseases continue to impose a substantial burden on healthcare systems, there is an increase in emphasis on early and accurate diagnosis for effective disease management.

Biomarkers, which are measurable indicators of biological processes or conditions, play a crucial role in disease diagnosis by providing valuable insights into the physiological state of an individual. Biomarkers facilitate early detection, risk assessment, and monitoring of disease progression, enabling timely intervention and personalized treatment strategies. For instance, Guardant Health, an American biotechnology firm, provides Guardant360 CDx test. Guardant360 CDx test is FDA-approved for complete genomic testing for all solid cancers. The test delivers comprehensive genomic results within 7 days of a basic blood test, helping doctors make informed treatment choices. Furthermore, technological advancements in genomics, proteomics, and metabolomics have broadened the range of biomarkers for clinical use, improving their effectiveness in diagnosis of various diseases. Thus, the rise in the incidence of chronic diseases is expected to drive the growth of the market.

The surge in adoption of biomarkers in the drug development process stands as a pivotal driver propelling the growth of the biomarkers market. Biomarkers, defined as measurable indicators of biological processes or responses to therapeutic interventions, have become indispensable tools in the drug development process. The ability of biomarkers to provide precise and real-time information about the physiological and molecular status of an organism has revolutionized the way pharmaceutical companies approach drug discovery and development. Biomarkers offer a means to objectively assess the efficacy, safety, and potential adverse effects of new drugs at various stages, from preclinical studies to clinical trials. This expedites the drug development timeline and enhances the probability of successful outcomes. For instance, according to the 2020 report by the National Library of Medicine, biomarkers are widely used at every stage of drug discovery and development. Utilization of biomarkers has a potential to make drug discovery, development, and approval processes more efficient. Thus, the rise in adoption of biomarkers in the drug discovery and development procedure is expected to contribute significantly to the growth of the market.

However, data security and privacy concerns have emerged as major concerns that restrain the growth of the market. The life sciences industry relies heavily on the collection, storage, and analysis of vast amounts of sensitive and confidential data, including patient records, clinical trial information, and genomic data. With the increase in digitization of healthcare processes and the adoption of advanced technologies, such as cloud computing and big data analytics, the risk of data breaches and unauthorized access has escalated. Thus, data security and privacy concerns are expected to restrain the growth of the market.

In addition, high development costs might restrain the growth of the market. The discovery and validation of biomarkers involve significant R&D costs. The high cost of developing and validating biomarkers negatively impacts the adoption of the biomarkers particularly in smaller companies.

The biomarkers market is segmented on the basis of type, application, service, and region. By type, the market is divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. By application, the market is divided into risk assessment, development of molecular diagnostic, disease diagnosis, drug discovery & development, drug formulation, forensic application, and others.

By service, it is classified into pharmaceutical & sample preparation, assay development, biomarker validation & testing, and other services. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, rest of LAMEA)

The major players profiled in the report are GE Healthcare, Abbott Laboratories, Inc., Bio-Rad Laboratories, Epistem Ltd., Eisai Co. Ltd., Roche Diagnostics Limited, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Aushon Biosystem, and Siemens AG.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biomarkers market analysis from 2023 to 2033 to identify the prevailing biomarkers market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biomarkers market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Market share analysis of players at global/region/country level
SWOT Analysis

Key Market Segments

By Type

Safety Biomarkers
Validation Biomarkers
Efficacy Biomarkers

By Application

Risk Assessment
Development of Molecular Diagnostic
Disease Diagnosis
Drug Discovery and Development
- Type
- Clinical Trial - Pre Clinical Phase and Phase 1
- Clinical Trial Phase 2
- Clinical Trial Phase 3
- Clinical Trial Commercial Phase
Drug Formulation
Forensic Application
Others

By Services

Sample Preparation
Assay Development
Biomarker Validation and Testing
Other Services

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific
Qiagen N.V
F. Hoffmann-La Roche AG
GE Healthcare
Revvity, Inc.
Abbott Laboratories
Siemens AG
Merck KGaA
Agilent Technologies Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. High adoption of biomarkers in drug discovery and development process.
  - 3.4.1.2. Surge in prevalence of chronic diseases.
  - 3.4.1.3. Rise in adoption of biomarkers in forensic analysis.
- 3.4.2. Restraints
  - 3.4.2.1. High cost of development of biomarkers.
- 3.4.3. Opportunities
  - 3.4.3.1. Collaborative efforts by private and government organizations for development of biomarkers.

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Efficacy Biomarkers
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Safety Biomarkers
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Validation Biomarkers
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Risk Assessment
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Development of Molecular Diagnostic
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Disease Diagnosis
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Drug Discovery and Development
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- 5.5.4. Drug Discovery and Development Biomarkers Market by Type
  - 5.5.4.1. Clinical Trial - Pre Clinical Phase and Phase 1 Market size and forecast, by region
  - 5.5.4.2. Clinical Trial Phase 2 Market size and forecast, by region
  - 5.5.4.3. Clinical Trial Phase 3 Market size and forecast, by region
  - 5.5.4.4. Clinical Trial Commercial Phase Market size and forecast, by region
5.6. Drug Formulation
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Forensic Application
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country
5.8. Others
- 5.8.1. Key market trends, growth factors and opportunities
- 5.8.2. Market size and forecast, by region
- 5.8.3. Market share analysis by country

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Sample Preparation
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Assay Development
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Biomarker Validation and Testing
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Other Services
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country

CHAPTER 7: BIOMARKERS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
  - 7.2.3.1. North America Drug Discovery and Development Biomarkers Market by Type
- 7.2.4. Market size and forecast, by Services
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by Services
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by Services
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by Services
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
  - 7.3.3.1. Europe Drug Discovery and Development Biomarkers Market by Type
- 7.3.4. Market size and forecast, by Services
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. UK
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by Services
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by Services
  - 7.3.5.3. Germany
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by Services
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by Services
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by Services
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by Services
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
  - 7.4.3.1. Asia-Pacific Drug Discovery and Development Biomarkers Market by Type
- 7.4.4. Market size and forecast, by Services
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by Services
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by Services
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by Services
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by Services
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by Services
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by Services
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
  - 7.5.3.1. LAMEA Drug Discovery and Development Biomarkers Market by Type
- 7.5.4. Market size and forecast, by Services
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by Services
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by Services
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by Services
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by Services

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Abbott Laboratories
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Agilent Technologies Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bio-Rad Laboratories, Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. GE Healthcare
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Siemens AG
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Thermo Fisher Scientific
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Qiagen N.V
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Merck KGaA
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. F. Hoffmann-La Roche AG
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Revvity, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance

バイオマーカーの世界市場：タイプ別、用途別、サービス別 - 機会分析・産業予測、2024～2033年

Biomarkers Market By Type, By Application, By Services : Global Opportunity Analysis and Industry Forecast, 2024-2033

利害関係者にとっての主なメリット

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章バイオマーカー市場：タイプ別

第5章バイオマーカー市場：用途別

第6章バイオマーカー市場：サービス別

第7章バイオマーカー市場：地域別

第8章競合情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Services

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

CHAPTER 7: BIOMARKERS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

バイオマーカーの世界市場：タイプ別、用途別、サービス別 - 機会分析・産業予測、2024～2033年

Biomarkers Market By Type, By Application, By Services : Global Opportunity Analysis and Industry Forecast, 2024-2033

利害関係者にとっての主なメリット

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 バイオマーカー市場：タイプ別

第5章 バイオマーカー市場：用途別

第6章 バイオマーカー市場：サービス別

第7章 バイオマーカー市場：地域別

第8章 競合情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Services

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

CHAPTER 7: BIOMARKERS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章バイオマーカー市場：タイプ別

第5章バイオマーカー市場：用途別

第6章バイオマーカー市場：サービス別

第7章バイオマーカー市場：地域別

第8章競合情勢

第9章企業プロファイル